文献速递外周动脉疾病颈动脉与弓上血管主动脉疾病

常见血管手术的医院成本上涨超过报销增幅

Rising hospital costs outpace reimbursement for common vascular procedures.
PubMed 文献 · J Vasc Surg · 2026-04-21

该研究回顾性分析了一个大型三级医疗系统2019至2022年五种常见血管手术的机构成本核算数据,发现直接医院成本增加约31%至32%,而报销仅增加20%至21%,导致每例贡献毛利(CTI)从2019年的1470美元降至2020-2022年的1177美元,下降20%。多种手术的利润率显著恶化,而手术量、支付方构成和住院时间保持稳定。

要点

  • 2019至2022年直接医院成本增加约31%至32%,报销仅增加20%至21%。
  • 每例CTI从2019年1470美元降至2020-2022年1177美元,下降20%。
  • 下肢血管造影介入、颈动脉内膜切除和EVAR的利润率恶化最显著。

核心结论

  • 常见血管手术的直接医院成本从2019到2022年大幅增加并显著超过报销增长,导致住院和门诊手术利润率逐步侵蚀。
  • 医院运营成本的结构性增加而非手术利用率变化是财务表现恶化的驱动因素。

研究设计与样本

  • 回顾性审查一个大型三级医疗系统2019至2022年五种常见血管手术的机构成本核算数据。
  • 五种手术包括动静脉瘘建立、动静脉移植物置入、颈动脉内膜切除、血管腔内主动脉修复和下肢血管造影经皮介入。
  • 财务数据来自STRATA Jazz财务分析平台,包括直接医院成本、报销和间接贡献(CTI),按每例标准化比较2019年与2020-2022年。

主要发现

  • 直接医院成本增加约31%至32%,报销仅增加20%至21%。
  • 总体每例CTI从2019年1470美元降至2020-2022年1177美元,下降20%。
  • 门诊手术直接成本增加23%,报销略有下降,CTI下降25%;住院手术直接成本增加32%,每例CTI下降12%。
  • 下肢血管造影介入的利润率下降67%,颈动脉内膜切除下降52%,血管腔内主动脉修复的利润率到2022年由正转负。
  • 手术量、支付方构成和住院时间在研究期间保持稳定。

临床怎么用

  • 血管外科项目需关注成本与报销的差距,评估手术利润率可持续性。
  • 针对利润率恶化显著的手术(如颈动脉内膜切除、下肢介入、EVAR)优化资源使用。
  • 倡导报销与复杂血管护理真实成本更匹配,以保障项目长期可持续。

局限性

  • 研究基于单一大型三级医疗系统的回顾性成本核算数据,结果外推需谨慎。
  • 原文未报告样本量、统计显著性检验及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hospitals across the United States have experienced rapidly increasing operating costs since the COVID-19 pandemic, driven by inflation, labor shortages, and rising supply and device expenses. Because vascular surgery care frequently relies on specialized procedural resources and serves a predominantly Medicare population, reimbursement growth may not adequately offset rising hospital costs. This study evaluated trends in hospital costs, reimbursement, and procedural margins for commonly performed vascular procedures within a large tertiary health system. METHODS: Institutional cost accounting data were retrospectively reviewed for five commonly performed vascular procedures performed between 2019 and 2022: arteriovenous fistula creation, arteriovenous graft placement, carotid endarterectomy, endovascular aortic repair, and lower extremity angiography with percutaneous intervention. Financial data were obtained from the STRATA Jazz financial analytics platform and included direct hospital costs, reimbursement, and contribution to indirect (CTI). Financial metrics were standardized per case and compared between the prepandemic baseline year (2019) and the combined postpandemic period (2020-2022). Secondary outcomes included procedural volume, length of stay, and payer mix. RESULTS: Direct hospital costs increased by approximately 31% to 32% between 2019 and 2022, whereas reimbursement increased by only 20% to 21%, resulting in substantial margin compression. Overall CTI decreased from $1470 per case in 2019 to $1177 during 2020-2022, representing a 20% decline. Outpatient procedures demonstrated a 23% increase in direct costs with a slight decline in reimbursement, resulting in a 25% reduction in CTI. Inpatient procedures demonstrated a 32% increase in direct costs and a 12% decline in CTI per case. Procedure-level analysis demonstrated marked margin deterioration across multiple interventions, including a 67% decline for lower extremity angiography with intervention, a 52% decline for carotid endarterectomy, and conversion of endovascular aortic repair margins from positive to negative by 2022. Procedural volumes, payer mix, and hospital length of stay remained stable throughout the study period. CONCLUSIONS: Direct hospital costs for commonly performed vascular procedures increased substantially from 2019 to 2022 and significantly outpaced reimbursement growth, resulting in progressive erosion of procedural margins across inpatient and outpatient vascular interventions. These findings suggest that structural increases in hospital operating costs, rather than changes in procedural utilization, are driving worsening financial performance. Greater alignment between reimbursement and the true costs of delivering complex vascular care will be necessary to ensure the long-term sustainability of vascular surgery programs.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Brinster CJ, Antunez C, Escousse GT, et al. Rising hospital costs outpace reimbursement for common vascular procedures. J Vasc Surg. 2026. PMID: 42025648. doi:10.1016/j.jvs.2026.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。